Novel betulin derivatives as antileishmanial agents with mode of action targeting type IB DNA topoisomerase

Molecular Pharmacology

Volumn 80, Issue 4, 2011, Pages 694-703

  Chowdhury, Sayan ^a   Mukherjee, Tulika ^a   Sengupta, Souvik ^a   Chowdhury, Somenath Roy ^a   Mukhopadhyay, Sibabrata ^a   Majumder, Hemanta K ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

3 O,28 O DIACETYL BETULIN; 3 O,28 O DIACETYL DIHYDROBETULIN; 3 O,28 O DICROTONYL BETULIN; 3 O,28 O DICROTONYLBETULIN; 3 O,28 O DIGLUTARYL BETULIN; 3 O,28 O DIGLUTARYL DIHYDROBETULIN; 3 O,28 O DIPHTHALOYL BETULIN; 3 O,28 O DISUCCINYL BETULIN; 3 O,28 O DISUCCINYL DIHYDROBETULIN; ANTILEISHMANIAL AGENT; ANTIMONY GLUCONATE; BETULIN; DIGLUTARYL DIHYDROBETULIN; DISUCCINYL BETULIN; DISUCCINYL DIHYDROBETULIN; DNA TOPOISOMERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; COMPLEX FORMATION; DISSOCIATION CONSTANT; DRUG BINDING; DRUG STRUCTURE; LEISHMANIA DONOVANI; MACROPHAGE; MOUSE; NONHUMAN; PARASITE; PRIORITY JOURNAL; STOICHIOMETRY;

ANIMALS; ANTIPROTOZOAL AGENTS; CELLS, CULTURED; CRICETINAE; DNA TOPOISOMERASES, TYPE I; DRUG DELIVERY SYSTEMS; LEISHMANIA DONOVANI; MICE; MICE, INBRED BALB C; TOPOISOMERASE I INHIBITORS; TRITERPENES;

EID: 80053197078     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.072785     Document Type: Article

References (39)

1. Acharya BR, Bhattacharyya B, and Chakrabarti G (2008) The natural naphthoquinone plumbagin exhibits antiproliferative activity and disrupts the microtubule network through tubulin binding. Biochemistry 47:7838-7845.
2. Alakurtti S, Heiska T, Kiriazis A, Sacerdoti-Sierra N, Jaffe CL, and Yli-Kauhaluoma J (2010) Synthesis and anti-leishmanial activity of heterocyclic betulin derivatives. Bioorg Med Chem 18:1573-1582.
3. Ashutosh, Sundar S, and Goyal N (2007) Molecular mechanisms of antimony resistance in. Leishmania. J Med Microbiol 56:143-153.
4. Basu R, Bhaumik S, Basu JM, Naskar K, De T, and Roy S (2005) Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174:7160-7171. (Pubitemid 40705683)
5. Bodley AL and Shapiro TA (1995) Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc Natl Acad Sci USA 92:3726-3730.
6. Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70:369-413.
7. Chowdhury AR, Mandal S, Goswami A, Ghosh M, Mandal L, Chakraborty D, Ganguly A, Tripathi G, Mukhopadhyay S, Bandyopadhyay S, et al. (2003) Dihydrobetulinic acid induces apoptosis in Leishmania donovani by targeting DNA topoisomerase I and II: implications in antileishmanial therapy. Mol Med 9:26-36. (Pubitemid 36667689)
8. Das BB, Sen N, Dasgupta SB, Ganguly A, and Majumder HK (2005) N-terminal region of the large subunit of Leishmania donovani bisubunit topoisomerase I is involved in DNA relaxation and interaction with the smaller subunit. J Biol Chem 280:16335-16344. (Pubitemid 40616762)
9. Das BB, Sen N, Ganguly A, and Majumder HK (2004) Reconstitution and functional characterization of the unusual bi-subunit type I DNA topoisomerase from Leishmania donovani. FEBS Lett 565:81-88. (Pubitemid 38595324)
10. Das BB, Sen N, Roy A, Dasgupta SB, Ganguly A, Mohanta BC, Dinda B, and Majumder HK (2006) Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I. Nucleic Acids Res 34:1121-1132.
11. Fortune JM and Osheroff N (2006) Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 64:221-253.
12. Ganguly A, Das BB, Sen N, Roy A, Dasgupta SB, and Majumder HK (2006) 'Leish- Man' topoisomerase I: an ideal chimera for unraveling the role of the small subunit of unusual bi-subunit topoisomerase I from Leishmania donovani. Nucleic Acids Res 34:6286-6297. (Pubitemid 44942749)
13. Haimeur A, Guimond C, Pilote S, Mukhopadhyay R, Rosen BP, Poulin R, and OuelletteM(1999) Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania. Mol Microbiol 34:726-735.
14. Huang CY (1982) Determination of binding stoichiometry by the continuous variation method: the Job plot. Methods Enzymol 87:509-525.
15. Kedzierski L (2010) Leishmaniasis vaccine: where are we today? J Glob Infect Dis 2:177-185.
16. Koster DA, Croquette V, Dekker C, Shuman S, and Dekker NH (2005) Friction and torque govern the relaxation of DNA supercoils by eukaryotic topoisomerase IB. Nature 434:671-674. (Pubitemid 40488562)
17. Laszczyk MN (2009) Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy. Planta Med 75:1549-1560.
18. Li CJ, Averboukh L, and Pardee AB (1993) beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J Biol Chem 268:22463-22468. (Pubitemid 23318296)
19. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375.
20. McConaughy BL, Young LS, and Champoux JJ (1981) The effect of salt on the binding of the eucaryotic DNA nicking-closing enzyme to DNA and chromatin. Biochim Biophys Acta 655:1-8.
21. Mishra M, Biswas UK, Jha DN, and Khan AB (1992) Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet 340:1256-1257.
22. Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9:338-350.
23. Nylén S and Gautam S (2010) Immunological perspectives of leishmaniasis. J Glob Infect Dis 2:135-146.
24. Olivier M, Gregory DJ, and Forget G (2005) Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view. Clin Microbiol Rev 18:293-305. (Pubitemid 40548295)
25. Osheroff N, Shelton ER, and Brutlag DL (1983) DNA topoisomerase II from Drosophila melanogaster. Relaxation of supercoiled DNA. J Biol Chem 258:9536-9543.
26. Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6:789-802.
27. Ray S, Hazra B, Mittra B, Das A, and Majumder HK (1998) Diospyrin, a bisnaphthoquinone: a novel inhibitor of type I DNA topoisomerase of Leishmania donovani. Mol Pharmacol 54:994-999. (Pubitemid 29002042)
28. Reutrakul V, Anantachoke N, Pohmakotr M, Jaipetch T, Yoosook C, Kasisit J, Napaswa C, Panthong A, Santisuk T, Prabpai S, et al. (2010) Anti-HIV-1 and anti-inflammatory lupanes from the leaves, twigs, and resin of Garcinia hanburyi. Planta Med 76:368-371.
29. Roy A, Das BB, Ganguly A, Bose Dasgupta S, Khalkho NV, Pal C, Dey S, Giri VS, Jaisankar P, Dey S, et al. (2008) An insight into the mechanism of inhibition of unusual bi-subunit topoisomerase I from Leishmania donovani by 3,3′-diindolylmethane, a novel DNA topoisomerase I poison with a strong binding affinity to the enzyme. Biochem J 409:611-622. (Pubitemid 351184980)
30. Seifert K, Pérez-Victoria FJ, Stettler M, Sánchez- Cañete MP, Castanys S, Gamarro F, and Croft SL (2007) Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents 30:229-235. (Pubitemid 47135625)
31. Sen N, Das BB, Ganguly A, Mukherjee T, Tripathi G, Bandyopadhyay S, Rakshit S, Sen T, and Majumder HK (2004) Camptothecin induced mitochondrial dysfunction leading to programmed cell death in unicellular hemoflagellate Leishmania donovani. Cell Death Differ 11:924-936. (Pubitemid 39139751)
32. Sindermann H and Engel J (2006) Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 100 (Suppl 1):S17-S20. (Pubitemid 44490164)
33. Solomon M, Pavlotsky F, Leshem E, Ephros M, Trau H, and Schwartz E (2011) Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venereol 25:973-977.
34. Steele JC, Warhurst DC, Kirby GC, and Simmonds MS (1999) In vitro and in vivo evaluation of betulinic acid as an antimalarial. Phytother Res 13:115-119. (Pubitemid 29129443)
35. Stewart L, Redinbo MR, Qiu X, Hol WG, and Champoux JJ (1998) A model for the mechanism of human topoisomerase I. Science 279:1534-1541. (Pubitemid 28217077)
36. Teicher BA (2008) Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol 75:1262-1271.
37. Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65:635-692.
38. Ward LD (1985) Measurement of ligand binding to proteins by fluorescence spectroscopy. Methods Enzymol 117:400-414.
39. Wortmann G, Zapor M, Ressner R, Fraser S, Hartzell J, Pierson J, Weintrob A, and Magill A (2010) Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 83:1028-1033.